Modelling genetic and clinical heterogeneity in epithelial ovarian cancers

被引:30
|
作者
Lawrenson, Kate
Sproul, Duncan [2 ]
Grun, Barbara [1 ]
Notaridou, Maria [1 ]
Benjamin, Elizabeth [3 ]
Jacobs, Ian J. [1 ]
Dafou, Dimitra [1 ]
Sims, Andrew H. [2 ]
Gayther, Simon A. [1 ]
机构
[1] UCL, Gynaecol Canc Res Labs, UCL EGA Inst Womens Hlth, London WC1E 6DD, England
[2] Western Gen Hosp, Appl Bioinformat Canc Grp, Edinburgh Breakthrough Res Ctr, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland
[3] UCL, Dept Histopathol, Inst Canc, London WC1E 6JJ, England
基金
英国医学研究理事会;
关键词
EXPRESSION PROFILES; BORDERLINE TUMORS; GROWTH-FACTOR; LOW-GRADE; C-MYC; MUTATIONS; CARCINOMA; CELLS; KRAS; TRANSFORMATION;
D O I
10.1093/carcin/bgr140
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The biology underlying early-stage epithelial ovarian cancer (EOC) development is poorly understood. Identifying biomarkers associated with early-stage disease could have a significant impact on reducing mortality. Here, we describe establishment of a three-dimensional (3D) in vitro genetic model of EOC initiation and early-stage neoplastic progression. Normal primary ovarian epithelial (POE) cells, immortalized using hTERT (immortalised ovarian epithelial [IOE] cells), were partially transformed by overexpressing the CMYC oncogene (IOECMYC cells). Subsequent expression of mutant alleles of KRAS (KRAS(G12V)) or BRAF (BRAF(V600E)) created double-mutant lines (IOECMYC.KRAS and IOECMYC.BRAF). The transformed phenotype of IOECMYC cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOECMYC cells had undergone morphological and phenotypic changes characteristic of neoplastic progression. When cultured as 3D spheroids, IOE cells underwent growth arrest, reminiscent of nonproliferative, unstimulated POE in vivo. In contrast, IOSECMYC+BRAF/KRAS cells formed highly proliferative, poly-aggregate spheroid structures, showing increased expression of the Wilms tumour 1 tumourigenic marker and MIB1 proliferation marker. Transcriptomic analyses identified different gene expression profiles between the different cell lines and novel candidate genes (e.g. RGS4, CTGF and THBS1) that are somatically altered in EOCs. Gene expression signatures were compared with signatures from primary EOCs; tumours with IOECMYC 'like' signatures were more likely to be high grade (P = 0.018); tumours with BRAF signatures were associated with improved relapse-free survival (P = 0.003). In conclusion, we have established in vitro 3D models of early-stage EOCs, which reflect genetic and phenotypic heterogeneity of the disease. Molecular genetic characteristics of these models correlated with molecular and clinical features of primary EOCs.
引用
收藏
页码:1540 / 1549
页数:10
相关论文
共 50 条
  • [1] Molecular characteristics and clinical behaviour of epithelial ovarian cancers
    Hollis, Robert L.
    CANCER LETTERS, 2023, 555
  • [2] A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
    Ceccaldi, Raphael
    O'Connor, Kevin W.
    Mouw, Kent W.
    Li, Adam Y.
    Matulonis, Ursula A.
    D'Andrea, Alan D.
    Konstantinopoulos, Panagiotis A.
    CANCER RESEARCH, 2015, 75 (04) : 628 - 634
  • [3] Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours
    Khalique, L.
    Ayhan, A.
    Weale, M. E.
    Jacobs, I. J.
    Ramus, S. J.
    Gayther, S. A.
    JOURNAL OF PATHOLOGY, 2007, 211 (03): : 286 - 295
  • [4] Epithelial ovarian cancers (advanced stage)
    Spano, JP
    Lucchi, E
    Sezeur, A
    Lhommé, C
    BULLETIN DU CANCER, 1998, : 5 - 23
  • [5] Hereditary breast and ovarian cancers: genetic testing and its clinical implications
    Pradnya, Kowtal
    Shilpa, Vyas
    Narendra, Joshi
    Sarin, Rajiv
    JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA, 2007, 57 (04): : 298 - 306
  • [6] The clonal evolution of metastases from primary serous epithelial ovarian cancers
    Khalique, Lalarukh
    Ayhan, Ayse
    Whittaker, John C.
    Singh, Naveena
    Jocobs, Ian J.
    Gayther, Simon A.
    Ramus, Susan J.
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (07) : 1579 - 1586
  • [7] Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas
    Craig, Olivia
    Nigam, Abhimanyu
    Dall, Genevieve V.
    Gorringe, Kylie
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2023, 13 (09):
  • [8] KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants
    Heublein, Sabine
    Grasse, Katinka
    Hessel, Harald
    Burges, Alexander
    Lenhard, Miriam
    Engel, Jutta
    Kirchner, Thomas
    Jeschke, Udo
    Mayr, Doris
    BMC CANCER, 2013, 13
  • [9] Mutational heterogeneity in non-serous ovarian cancers
    Teer, Jamie K.
    Yoder, Sean
    Gjyshi, Anxhela
    Nicosia, Santo V.
    Zhang, Chaomei
    Monteiro, Alvaro N. A.
    SCIENTIFIC REPORTS, 2017, 7
  • [10] Clinical significance of ascites in epithelial ovarian cancer
    Huang, H.
    Li, Y. J.
    Lan, C. Y.
    Huang, Q. D.
    Feng, Y. L.
    Huang, Y. W.
    Liu, J. H.
    NEOPLASMA, 2013, 60 (05) : 546 - 552